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Abstract
Background: The aim was to describe the regulatory B and T cells (Breg and Treg) and T helper 17 (Th17)
lymphocytes before and under treatment with biologic drugs, and to assess their potential predictive value as
biomarkers of response in rheumatoid arthritis (RA).
Methods: This was a non-randomised, single-centre, prospective study. Patients with active RA (American College
of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 2010) who required the initiation or switch
to any biologic drug except rituximab were included. The main judgement criterion was the frequency and absolute
number of CD24hiCD27+ Breg and CD24hiCD38hi T2/Breg cells, CD25hiCD127low Treg and CD45RA−CD161+CCR6+ Th17
cells measured at inclusion in both patients and controls, and after 1, 3 and 6 months of treatment (M1, M3 and M6) in
patients with RA, and compared with the M6 response to treatment (EULAR response and Disease Activity Score in 28
joints (DAS28) remission).
Results: Thirty-one patients with RA and 17 controls were included. There was a reduction in T2/Breg frequency at
M0 in patients (p < 0.001) and absolute numbers (p = 0.014) and in immunopositive vs. immunonegative RA (p = 0.016).
DAS28 remission at M6 was associated with increased frequency of Treg (p = 0.01). A higher level of CD24hiCD27+
Breg at baseline was associated with DAS28 remission at M6 (p = 0.04) and a good EULAR response at M6 for
abatacept-treated patients (p = 0.01). A lower M0 level of Th17 was associated with a good EULAR response at
M6 (p = 0.007), notably under anti-cytokine drugs (p = 0.048).
Conclusions: Altogether, these data, although preliminary, suggest that phenotyping of T and B cells has
potential value for the stratification of biologic drugs, notably with respect to choosing between abatacept and
anti-cytokine blockade.
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Background
The development of different targeted immunotherapies
and treatment strategies (treat to target (T2T) and tight
control) has allowed significant improvement in the
prognosis of rheumatoid arthritis (RA), and long-lasting
clinical remission may now be a consideration [1]. Ap-
proximately one third of patients, however, experience
primary non-response or insufficient response to these
different drugs [2, 3]. The search for biomarkers that
could predict response to biologic drugs is therefore
crucial, in order to ensure that the treatment chosen
will be sufficiently effective to halt the progress of the
disease, whilst avoiding prescribing patients ineffective,
potentially deleterious (leading to infectious or neoplas-
tic complications, etc.) and expensive treatment [4].
Different lymphocyte subpopulations play a major
role in the physiopathology of RA, such as regulatory T
cells (Treg), T helper 17 (Th17) cells and regulatory B
lymphocytes (Breg). In the physiological condition,
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CD4 + CD25hiFoxP3+ regulatory T cells constitute 5–
10% of the population of CD4+ T lymphocytes in the
blood [5]. A functional deficit in Treg with a reduction
of their suppressive activity has been observed in RA [6].
A loss of Treg capacity to suppress effector CD4+CD25−
T cells has been observed, prior to anti-TNF treatment
for active RA, and a recovery of this defect was observed
in patients who respond clinically to anti-TNF drugs
with a quantitative increase in Treg frequencies post
treatment [6]. Moreover, the quantitative restoration of
the Treg upon achieving remission with anti-TNF has
been associated with greater probability of long-term
remission [7]. An increase in T lymphocytes, and Treg
in particular, was furthermore recorded after the use of
abatacept, a biologic drug that reproduces the physio-
logical inhibitor role of CTLA4 [8].
The identification of the Th17 lymphocytes, a subpopu-
lation of CD4+ T-lymphocytes that produces the highly
proinflammatory cytokine IL-17 [9, 10], opened the way
for new understanding of the physiopathological and new
treatment options (secukinumab or ixekizumab) for RA
[11, 12]. Th17 cells are characterised by considerable plas-
ticity (interconversion with Th1 cells), which themselves
can also develop into Th17 under some pathophysio-
logical circumstances [13–16]. An inverse correlation
between blood Th17 and anti-citrullinated peptide anti-
bodies (ACPA) levels has been observed in patients with
RA [17], illustrating the interrelationship between this
subpopulation and humoral immunity in this auto-
immune rheumatism. The role of Th17 appears to be
particularly relevant during the onset of RA and later
may be influenced by treatments, increasing under
methotrexate (MTX) [18] and decreasing in patients that
do not respond to infliximab [19].
B lymphocytes and humoral immunity also play a key
role in RA, notably with ACPA and rheumatoid factor
(RF) production [20]. Breg, by analogy to Treg, represent
a subpopulation of B cells that have immune-regulating
properties [21] and play a role in peripheral tolerance
[22], mainly via the substantial secretion of IL-10 [22, 23].
Discrepancies in the phenotype of human Breg have been
described [24–28], although the most commonly accepted
is the inclusion of putative Breg within the immature
transitional T2 population (CD19+CD24hiCD38hi). Add-
itional regulatory properties have been described in the
memory B cells CD24hiCD27+ phenotype (also produ-
cing IL-10) [29]. These cells are reported to be able to
inhibit the proliferation of CD4+ T cells differentiating
between Th1 and Th17 cells, producing different proin-
flammatory cytokines. Although they are reported to be
quantitatively and functionally altered in patients with
active RA (reduction of their capacity to induce both
Treg from CD4+ and prevent the conversion of Treg
into Th17 cells) [30, 31], a recent report observed that a
high baseline level of Breg appeared to be predictive of a
clinical European League Against Rheumatism (EULAR)
response at 3 months upon anti-TNF treatment [25].
Thus, the main aim of our study was to describe the
different lymphocyte subpopulation frequencies in RA
(regulatory B and T cells and Th17 lymphocytes) before
and under biologic drugs, in order to test the correlation
with subsequent response to the drug received and to




Patients who met the American College of Rheumatology
(ACR)/EULAR 2010 criteria for RA [32] with active dis-
ease despite receiving a conventional synthetic or biologic
disease-modifying antirheumatic drug (DMARD) and who
required the initiation or a switch to any biologic drug ex-
cept rituximab, in association with MTX, were prospect-
ively included in this study. The exclusion criteria were
the use of corticosteroid therapy, concurrent or within the
last 3 months, at a dose of more than 10 mg/day or treat-
ment with other immunosuppressive therapy than MTX.
At least five half-lives were required before changing the
treatment if a biologic drug was previously used. Adult pa-
tients with a confirmed “mechanical” pathologic condition
(osteoporosis, osteoarthritis, etc.) who did not have a per-
sonal medical history of neoplastic, inflammatory or infec-
tious diseases were included as controls. All patients and
controls signed a consent form to participate in this study,
approved by the medical ethics committee of Amiens
University hospital, France (number 2015-000833-64).
Different parameters were gathered at inclusion (month
0 (M0)): history and treatments, body mass index (BMI),
disease activity evaluated by calculation of the Disease
Activity Score in 28 joints (DAS28) and the Health As-
sessment Questionnaire (HAQ), the erosive nature of the
RA (evaluated on radiographs of both hands and feet), the
autoimmune status (RF and ACPA assessed by anti-cyclic
citrullinated peptide (anti-CCP2 tests)), complete blood
count (CBC), measurement of C-reactive protein (CRP)
and erythrocyte sedimentation rate (ESR). Patients under-
went the same clinical and biological monitoring at 1
(M1), 3 (M3) and 6 months (M6) following treatment.
Analysis of lymphocyte subpopulations by flow cytometry
Flow cytometry (CMF) was used to conduct lymphocyte
phenotyping of fresh blood (Navios A80706, 3 lasers, 10
colours) at M0 in patients and controls and then at M1,
M3 and M6 in patients only. We used standard protocols
developed under routine immunology hospital services with
a view to be able to transfer data into clinical practice with
limited additional work. The following monoclonal anti-
bodies conjugated with a fluorochrome were used for the
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B cell phenotyping: CD19-AA750 (APC-AlexaFluor750),
CD24-PC5.5 (phycoerythrin-cyanine) and CD27-PC7,
CD38-APC (allophycocyanin). The following antibodies
were used for T cell phenotyping: CD3-AA750, CD4-PB,
CD45RA-FITC, CD62L-ECD, CD25-PC5.5, CD161-PC7,
CD127-AA700 and CCR6(CD196)-APC. All the anti-
bodies came from Beckmann-Coulter® (except CCR6-
APC from BioLegend®). At least 20,000 cells were
analysed for each sample.
The T and B cell populations were identified on the
single-parameter expression of CD3 and CD19, respect-
ively, combined with scatter (gating strategies are de-
scribed in Fig. 1). Regulatory B cells were defined as
CD19+CD24hiCD38hi further referred to as T2/Breg. We
also assessed the CD19+CD24hiCD27+ subpopulations.
Treg were identified as the CD4 + CD25hiCD127low sub-
population as previously described [33]. Th17 cells were
identified as subpopulation CD45RA+CD161+CCR6+
within the CD3 + CD4+ T cell gate. The results were
expressed as percentage of the parental lineage gate and
absolute value per millimeter cubed.
Statistical analysis
The characteristics of patients and controls were re-
corded as a percentage for the category-based variables
and as the median and 25th and 75th percentiles (inter-
quartile range (IQR)) for continuous variables. The
differences in percentage or absolute value of the
lymphocyte subpopulations were evaluated using the
parametric t test, the non-parametric Mann–Whitney
or Wilcoxon tests for matched data, or the Friedman
test for multiple comparisons. Correlation between the
different lymphocyte subpopulations was evaluated
using the Spearman test. The general linear model
(GLM) and MIXED procedures were used for the re-
petitive analysis models. We used p < 0.05 as the signifi-
cance threshold for the statistical tests, corrected by the
number of tests carried out, where necessary. The stat-
istical analyses were carried out using the Statistical
Package for Social Sciences (SPSS) and Statistical Ana-
lysis System (SAS) 9.3 software.
Results
Baseline characteristics of patients and controls
Table 1 gives the demographic and clinical characteristics
of the 31 patients and 17 controls, included prospectively
between November 2014 and October 2015. No statisti-
cally significant difference was observed. Two patients left
the study at M1 and three left at M6.
Baseline lymphocyte subpopulations levels in patients
and controls
We compared the frequencies of lymphocyte subpopula-
tions in patients before the use of biologic drugs with
those in controls (Table 2). The only statistically signifi-
cant differences were in T2/Breg cells, which were lower
in patients, both in frequency (%, p < 0.01) and in abso-
lute numbers (p < 0.05), and Th17 frequency (p < 0.05).
Association between the immunologic and radiographic
status of patients and their lymphocyte subpopulations
at baseline
We compared the frequencies of lymphocyte subpopula-
tions before the use of biologic drugs in patients with
positive (n = 23) or negative (n = 8) RF, positive (n = 25)
Fig. 1 Analysis of lymphocyte subpopulations by flow cytometry:
gating strategy. A Gating strategy for B lymphocytes; a expressed as
a single parameter of CD19 and scatter; b T2/Breg (CD24hiCD38hi);
c CD24hiCD27+ Breg. B Gating strategy for T lymphocytes; a CD3+CD4+;
b Treg (CD25hiCD127low); c CD4+45RA−; d Th17 (CD45RA−CD161+CCR6+).
Breg B regulatory cells, Treg T regulatory cells, Th17 T helper 17
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or negative (n = 6) ACPA and with or (n = 13) or without
(n = 18) structural damage. There was an association
between the presence of RF and lower absolute numbers
of T2/Breg (p = 0.016) with a median of 10.99/mm3
(8.12–16.58) for RF+ patients vs. 23.1/mm3 (16.03–
24.74) for RF- patients. No further association was found
between other lymphocyte subpopulations and ACPA or
radiographic status.
Correlation between lymphocyte subpopulation levels in
patients and controls
We tested potential correlation between T2/Breg, Treg
and Th17 frequencies or absolute values, in controls
and patients at different time points during treatment.
In controls (n = 17), there was a trend toward correl-
ation between the absolute number of Treg and T2/
Breg (r = 0.500, p = 0.041) and between Treg and Th17
cells (r = 0.740 and p = 0.001).
In patients at baseline (n = 31), the positive correl-
ation between absolute numbers of Treg and Th17 cells
was confirmed (r = 0.579, p = 0.001) and between
CD24hiCD27+ B cells and Th17 cells (r = 0.375, p =
0.037). At M1, there was positive correlation between
absolute numbers of Treg and Th17 cells (r = 0.466, p =
0.011) and at M6 (r = 0.497 and p = 0.010); between
absolute values of T2/Breg and Th17 cells at M1 (r =
0.385 and p = 0.039) and at M3 in percentage values (r =
0.383 and p = 0.040) and positive correlation between
absolute values of CD24hiCD27+ Breg and Th17 cells
only at M1 (r = 0.513 and p = 0.004).
Evolution of lymphocyte subpopulations levels under
biologic drugs
We compared the evolution of the lymphocyte subpop-
ulations in patients between M0 (n = 31), M1 (n = 29),
M3 (n = 26) and M6 (n = 26). We observed a difference
Table 1 Baseline characteristics of patients and controls
Patients with RA (n = 31) Control group (n = 17) p
Women 58.1% (n = 18) 41.2% (n = 7) 0.367
Age 57 (48–61)a 41 (29–68)a 0.131
BMI (kg/m2) 25.8 (22.2–33)a 24.0 (22.16–26.30)a 0.343
Medical history of smoking 48.4% (n = 15) 23.5% (n = 4) 0.127
Consumption (packets per year) 20 (11–28)a 0 (0–5)a 0.094
Recent RA ≤2 years 32.3% (n = 10) -
Antibodies
RF+ 74.2% (n = 23) -
ACPA+ 80.6% (n = 25) -
Structural damage (erosions) 41.9% (n = 13) -
NSAID 12.9% (n = 4) -
Corticoids 54.8% (n = 17) -
Median dosage (mg/day) 5 (5–6)a -
Methotrexate 64.5% (n = 20) -
Median dose (mg/week) 15 (10–20)a -
Initiation (1st line of biomedicine) 54.8% (n = 17) -
Abatacept 38.7% (n = 12) -
Tocilizumab 19.4% (n = 6) -
Anti-TNF drugs Golimumab 16.1% (n = 5) -
Etanercept 22.6% (n = 7) -
Certolizumab 3.2% (n = 1) -
ESR (mm) 14 (6–31)a -
CRP (mg/L) 7.9 (3.0–23.2)a -
DAS28 4.24 (3.70–5.32)a -
DAS28-CRP 4.42 (3.69–5.11)a -
HAQ 1.63 (1–2)a -
aResults expressed as median and 25th and 75th percentiles. The Mann–Whitney test was used for quantitative variables; the Fisher exact test was used for other
variables (male/female, tobacco precursor). RA rheumatoid arthritis, BMI body mass index, RF rheumatoid factor, ACPA anti-citrullinated peptide antibodies, ESR erythrocyte
sedimentation rate, CRP C-reactive protein, DAS28 Disease Activity Score in 28 joints, HAQ Health Assessment Questionnaire, NSAID nonsteroidal anti-inflammatory drugs
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only in Treg percentage between the four measure-
ment times (p = 0.048). No significant evolution be-
tween the different treatment duration was observed
for percentage or for absolute numbers in any of the
other subsets (Table 3).
We then compared the evolution of the lymphocyte
subpopulations according to the type of treatment re-
ceived: (1) abatacept, an “anti-costimulation” treatment
(n = 12) vs. “anti-cytokine” (n = 19) comprising anti-TNF
(n = 13) and tocilizumab (n = 6) and then (2) anti-TNF
drug (n = 13) vs. abatacept and tocilizumab (n = 18). We
observed that Treg frequencies significantly decreased
over time under abatacept (p < 0.001), from a M0 me-
dian of 6.37% (5.26–7.23) to 4.68% (4.32–5.70) at M6;
while the frequencies of Treg increased under anti-TNF
drugs between M0 and M6 (p = 0.005), from a median of
6.49 (4.77–8.49) to 7.13 (6.69–7.95).
Baseline levels and evolution of lymphocyte
subpopulations in patients according to the DAS28
remission at M6
We attempted to determine whether the initial level of
the different lymphocyte subpopulations studied was as-
sociated with DAS28 remission at M6. We dichotomised
patients who achieved DAS28 remission (Fig. 2, dark
grey box plot (n = 7)), or not (white box plot, (n = 19))
at M6. We then observed the evolution of these differ-
ent populations at M1, M3 and M6. A higher baseline
frequency of CD24hiCD27+ B cells was associated with
DAS28 remission at M6 (p = 0.04) (Fig. 2a) with a me-
dian of 24.13% (20.04–27.34) for the patients in remis-
sion at M6 vs. 15.66% (12.31–27.72) for the others. The
Treg increased during treatment in patients achieving
DAS28 remission at M6 (p = 0.01), their median in-
creasing from 4.76% (4.21–7.89) at M0 to 6.90% (6.43–
7.22) at M6 (Fig. 2b).
Baseline levels and evolution of lymphocyte
subpopulations in patients according to the EULAR
response at M6
We repeated this analysis with respect to achieving a
good response (n = 9) or not (n = 17) using EULAR
criteria at M6. A higher baseline frequency of
CD24hiCD27+ B cells was associated with a good
EULAR response at M6 but this was not statistically
significant (p = 0.130), with a median of 26.79% (8.13–
28.64) at M0 in patients with a good EULAR response
at M6 vs. 14.22% (11.66–22) in the others.
Table 2 Initial lymphocyte subpopulations levels in patients with RA and controls
Lymphocyte populations Patient group (n = 31) Control group (n = 17) p
Lymphocytes
(%) 23.8 (17.0–30.0) 18.6 (13.6–28.5) 0.413
(/mm3) 1600 (1300–2000) 1700 (1050–1950) 0.974
B lymphocytes
(%) 11.1 (8.2–17.6) 10.0 (7.3–14.4) 0.651
(/mm3) 156 (95–278) 151 (122–195) 0.957
TCD4+
(%) 53.5 (47.0–60.9) 51.7 (44.8–58.1) 0.779
(/mm3) 723 (569–1081) 739 (549–955) 0.821
T2/Breg
(%) 8.5 (5.9–10.5) 13.8 (10.9–15.6) <0.001**
(/mm3) 13 (9–22) 17 (14–31) 0.014*
CD24hiCD27+ Breg
(%) 16.3 (13.1–28.6) 18.8 (11.9–24.5) 0.612
(/mm3) 33 (20–45) 23 (19–34) 0.185
Treg
(%) 6.4 (4.9–8.1) 7.1 (6.3–8.3) 0.223
(/mm3) 49 (35–65) 56 (44–68) 0.371
Th17
(%) 19.6 (13.2–22.7) 23.4 (18.6–28.4) 0.036*
(/mm) 77 (45–97) 76 (51–135) 0.539
Total lymphocytes, B lymphocytes, T2/B regulatory cells (Breg), CD24hiCD27+ Breg, T regulatory cells (Treg) and T helper 17 (Th17) observed in patients with
rheumatoid arthritis (RA) and controls in absolute value (cells per mm3) and percentage; expressed in median and IQR; difference observed between the two
groups as per the Mann–Whitney test. *p < 0.05. **p < 0.001
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A trend was observed in favour of a higher frequency of
CD24hiCD27+ B cell in percentage at each of the treat-
ment duration time points in patients with a good EULAR
response at M6 vs. the others (p = 0.07) (Fig. 2c).
A lower frequency of Th17 cells before treatment was
significantly associated with a good EULAR response at
M6 (p = 0.007) with a median of 13.73% (12.1–19.57) at
M0 in patients with a good EULAR response at M6 vs.
20.66% (17.92–26.16) in the others. An identical trend
was observed in absolute numbers (p = 0.06) with a Th17
median of 13.73/mm3 (12.1–19.57) for patients with a
good response at M6 vs. 20.66/mm3 (17.92–26.16) for the
others. Likewise, a significantly lower frequency of Th17
cells was recorded at each treatment duration time point
in patients with a good EULAR response at M6 vs. the
others (p = 0.009), and the same trend was observed in ab-
solute numbers (p = 0.06) (Fig. 2d).
The initial level of T2/Breg and Treg cells was not asso-
ciated with good EULAR response at M6. Finally, there
was no significant difference in the evolution of the other
lymphocyte subpopulations under treatment, whether the
patient did or not have a good EULAR response at M6.
Baseline lymphocyte subpopulations levels according to
type of biologic drugs used
We analysed out data again with respect to good EULAR
response at M6, according to the type of biologic drug
received, i.e. abatacept (n = 10), anti-cytokine (anti-TNF
drugs and tocilizumab, (n = 16)) or anti-TNF drugs only
(n = 10). The proportion of patients with a good EULAR
response at M6 was 4/10 with abatacept, 2/6 with toci-
lizumab and 3/10 with anti-TNF drugs.
A high frequency of CD24hiCD27+ B cells was associ-
ated with a good EULAR response at M6 under abatacept
(p = 0.01) (Fig. 3a), with a median of 26.79% (10.29–30.43)
for patients with good response vs. 13% (10.32–15.19).
The initial level of the other lymphocyte subpopulations
was not associated with this response. A low initial level
of Th17 cells was associated with a good EULAR response
at M6 with the use of anti-cytokine (Fig. 3b, p = 0.048)
with a median of 13.73% (12.1–21.13) in patients with
good response vs. 20.62% (18.55–25.08) in the others. The
initial level of the other lymphocyte subpopulations was
not associated with this response.
Discussion
Our data describe the effects of biologic drugs on B cells
(CD24hiCD27+ Breg and T2/Breg), Treg and Th17 sub-
sets, immuno-regulating lymphocyte subpopulations, in-
volved in numerous autoimmune pathologic conditions
such as RA. In our study, participants were representative
of the patients commonly encountered in clinical practice
(2/3 women, median age approximately 60 years). One
third of the RA had developed within the previous 2 years.
Table 3 Evolution of lymphocyte subpopulations levels in patients with RA under biologic drugs
Lymphocyte populations Patients M0 (n = 31) Patients M1 (n = 29) Patients M3 (n = 29) Patients M6 (n = 26) p (6 months)
Lymphocytes
(%) 23.8 (18.2–29.9) 29.8 (17.9–36.7) 28.9 (22.9–33.4) 29.55 (20.95–36.8) 0.140
(/mm) 1600 (1300–2000) 1600 (1300–2200) 1900 (1500–2300) 1550 (1300–1900) 0.117
B lymphocytes
(%) 11.07 (8.28–16.05) 11.60 (8.94–17.47) 12.42 (8.44–15.96) 10.365 (8.38–14.52) 0.077
(/mm3) 156.15 (95.5–270.2) 201.57 (143.02–314.80) 192.63 (122.65–260.56) 180.66 (119.86–255.99) 0.989
T2/Breg
(%) 8.46 (5.95–10.35) 6.43 (4.31–9.92) 8.54 (6.35–12.5) 9.35 (5.93–12.65) 0.099
(/mm) 12.75 (8.88–21.15) 13.47 (8.85–24.43) 15.29 (9.06–28.36) 15.81 (8.40–22.83) 0.489
CD24hiCD27+ Breg
(%) 16.34 (13.2–27.71) 18.53 (15.02–31.61) 20.16 (14.81–30.26) 23.33 (14.02–33.00) 0.246
(/mm3) 33.26 (20.1–43.84) 34.87 (23.29–65.00) 35.22 (22.38–66.29) 35.54 (17.28–55.98) 0.813
Treg
(%) 6.37 (4.91–7.98) 5.41 (4.36–7.06) 5.54 (4.63–6.85) 6.38 (4.87–7.02) 0.048*
(/mm3) 49.40 (37.6–62.52) 40.36 (30.60–60.24) 47.7 (35.89–65.28) 51.20 (34.97–66.14) 0.702
Th17
(%) 19.57 (13.4–22.48) 19.0 (12.87–24.39) 19.01 (14.63–23.90) 19.50 (14.40–25.85) 0.928
(/mm3) 76.85 (49.1–96.77) 76.4 (47.75–112.7) 77.10 (61.80–113.43) 77.27 (65.66–91.44) 0.958
Total lymphocytes, B lymphocytes, T2/B regulatory cells (Breg), CD24hiCD27+ Breg, T regulatory cells (Treg) and T helper 17 (Th17) cells observed in absolute
value (cells/mm3) and percentage (%) at different stages of the treatment, i.e. M0 (n = 31), M1 (n = 29), M3 (n = 29) and M6 (n = 26) and the difference observed;
expressed as median and IQR, Kruskall −Wallis test. RA rheumatoid arthritis. *p < 0.05
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The median DAS28 was 4.24 and 3/4 of the subjects had
immunopositive (RF and/or CCP+) RA and almost 50% of
them had erosive RA.
In our study, T2/Breg cells were significantly reduced,
both in percentage and in absolute numbers, in patients
compared with controls. Other studies report a quantita-
tive decrease in Breg in patients with RA compared to
healthy control subjects and in patients with active RA
compared with inactive disease [30, 31]. This lympho-
cyte subpopulation may therefore represent an objective
biomarker of the activity of the disease. Moreover, we
observed positive correlation in absolute numbers
between T2/Breg and Treg cells in controls but not in
patients, both at inclusion and during treatment, which
may reflect dysfunction of the T2/Breg-Treg cell bal-
ance in RA. The T2/Bregs were also lower in patients
with RF, as described in another study [30], in which
negative correlation was observed between Bregs and
RF and ACPA levels. There is no consensus as yet on
the role of these antibodies in RA, but it has been
proven that their presence is a marker of poor progno-
sis. Our data showing lower T2/Breg levels in patients
with RA compared to controls, and in RF+ patients with
RA, may therefore indicate a “protective” role.
Fig. 2 Baseline levels and evolution of lymphocyte subpopulations in patients with rheumatoid arthritis according to Disease Activity Score
in 28 joints (DAS28) remission or European League Against Rheumatism (EULAR) response at month (M)6. a Baseline levels and evolution of
CD24hiCD27+ B regulatory cells (Breg) in percentage between M0 and M6 in the patients who achieved DAS 28 remission (n = 7) or not (n = 19)
at M6. b Initial levels and evolution of T regulatory cells (Treg) in percentage between M0 and M6 in the patients who achieved DAS28 remission
(n = 7) or not (n = 19) at M6. c Initial levels and evolution of CD24hiCD27+ Breg in percentage between M0 and M6 in patients who achieved
good EULAR response at M6 (n = 9) or not (n = 17). d Baseline levels and evolution of T helper 17 (Th17) cells in percentage between M0 and
M6 in patients who achieved good EULAR response at M6 (n = 9) or not (n = 17). Results in box plots are median and IQR; difference observed
between the two groups was assessed by the Mann–Whitney test at M0 and the general linear model (GLM) procedure and MIXED SAS for
repetitive analyses. *p < 0.05, **p < 0.01
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DAS28 remission at M6 was associated with signifi-
cantly higher CD24hiCD27+Breg frequency at baseline.
Likewise, higher CD24hiCD27+ Breg frequency was ini-
tially observed in patients who had a good EULAR re-
sponse at M6 (although not significant). The literature
suggests that higher pre-treatment levels of CD24hiCD27+
Breg and T2/Breg may be predictive of a good EULAR
response at 3 months with anti-TNF treatment [25]. A
retrospective study of patients with RA receiving abata-
cept, showed that the level of CD24hiCD27+ Breg prior to
treatment was not significantly different between patients
who were EULAR responders and non-responder patients
at M6 [34], whereas our results showed that a high initial
level of CD24hiCD27+ Breg is significantly associated with
a good EULAR response at M6 under abatacept. There-
fore, CD24hiCD27+ Breg, that were higher at M0 in pa-
tients with DAS28 remission and in patients with good
EULAR responses at M6, may represent a predictive bio-
marker for response to treatment, notably with abatacept.
Finally, the activity of the disease (evaluated by DAS28)
correlated negatively with the proportion of T2/Breg cells
(and CD5+CD1dhi [25] and IL-10 + CD5Cd1dhi and IL-
10+TIM-1+ [30, 31]) which also suggest a potential of
this subset for disease monitoring.
Several studies reported more Treg in healthy subjects
than in patients with early RA, but others reported simi-
lar levels [35–37]. Our data showed no significant differ-
ence in Treg at baseline between the patients and the
controls, most likely due to the small number of partici-
pants in our current work, as we previously identified
significant differences with larger numbers of subjects
[38]. Whereas the frequency of Treg cells was similar at
baseline in patients treated with the different drugs
(anti-TNF, tocilizumab and abatacept), we observed a
decrease in Tregs under abatacept but an increase under
anti-TNF drugs. As previously described [6, 7], this may be
partly explained by the removal of the repression exerted
by this major proinflammatory cytokine on these cells.
In our study, the pre-treatment level of Treg was not
predictive of DAS28 remission or EULAR response at
M6. However, we observed a significant evolution of
Treg under biologic drugs, with a recovery of these cells
in patients with DAS28 remission at M6. Their level is
described in the literature as being higher in drug-naive
patients with early disease, who will achieve remission
with MTX [38] and recovery of these cells under anti-
TNF drugs was associated with a greater probability of
long-term remission on anti-TNF drugs [7]. Other au-
thors also report an increase in Treg over the course of
anti-TNF [6] and abatacept [8] treatment only in pa-
tients with a good response. Treg may therefore repre-
sent an efficient biomarker for monitoring patients but
not for predicting their personal response.
Th17 cell levels were significantly lower in patients
than in the control group. Another study, however,
described elevated levels of Th17 cells in RA, but only in
patients with recent onset of disease [18]. There is a
large amount of literature on such quantification with
major discrepancies due to the use of different tech-
niques (with or without a polarization-inducing condi-
tion) and the use of different phenotypes to identify
Th17 cells [39, 40]. We did not find any association be-
tween the level of Th17 cells and the presence or ab-
sence of ACPA, although inverse correlation between
the frequency of Th17 cells in the blood and the ACPA
level had been previously described [17]. In addition,
there was positive correlation between the absolute
numbers of CD24hiCD27+ Breg and Th17 cells in pa-
tients with RA at baseline, but not in the controls. This
was no longer observed after 3 and 6 months of treat-
ment. This would therefore suggest initial pathologic
correlation in RA, which disappeared over the course of
a biology-modifying treatment such as a biologic drug.
Reduction in Th17 cells under MTX [18] and increase
in non-response to infliximab [19] have been described
In our study, patients with a good EULAR response at
M6 had a significantly lower frequency of Th17 cells
compared with moderate responders or non-responders,
both at inclusion and at all the treatment points. A small
proportion of Th17 cells at baseline was associated with a
good EULAR response at M6 under anti-cytokine treat-
ments but not under abatacept. The levels also did not
evolve under treatment, whether the patients responded
or not, which possibly reflects a lack of implication of
this cell population in RA at late stages of the disease
continuum (i.e. DMARD-resistant, biologic-drug-naive),
which appears to contribute to the explanation of the
Fig. 3 Baseline lymphocyte subpopulation levels according to the
European League Against Rheumatism (EULAR) response at month 6
(M6) by type of biologic drug. a Comparison of baseline levels of
CD24hiCD27+ B regulatory cells (Breg) in percentage, between the
patients who achieved a good EULAR response at M6 (n = 4) or not
(n = 6) under abatacept. b Comparison of T helper 17 cell (Th17)
levels in percentage at M0 between patients who achieved good
EULAR response at M6 (n = 5) or not (n = 11) under anti-cytokine
treatment; box-plots show median and IQR; difference observed
between the two groups using the t test. *p < 0.05
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disappointing results with treatments targeting IL-17 in
clinical trials among patients with established RA [41].
In contrast, the positive correlation between the absolute
numbers of Treg and Th17 cells, both in the controls
and in the patient groups is likely to reinforce the hy-
pothesis of an early role of Th17 cells in establishing
chronicity [18]. It should finally be noted that low levels
of Th17 cells may have predictive value for response to
“anti-cytokine” treatments.
Conclusions
This work aimed to establish pilot data using routine
immunology hospital services protocols towards describ-
ing the evolution of different lymphocyte subpopulations
in patients with RA under biologic drugs with different
mechanisms of action, and assessing whether there is
correlation between their levels and the later therapeutic
response. Whereas, to date, only RF and ACPA are used
to attempt to stratify patients for personalised treatment,
CD24hiCD27+ B cells and Th17 cells may offer predict-
ive value as biomarkers of therapeutic response under
biologic drugs and may be able to guide clinicians in
their choice of a tailored treatment. If validated, our data
would suggest the prescribing of abatacept if the patient
has high baseline levels of CD24hiCD27+ B cells, whereas
a low initial level of Th17 cells may guide the choice of
an anti-cytokine. As this was a pilot study, it remains
crucial that our results are confirmed on a wider scale
before being used to guide our therapeutic strategies.
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